A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood
1期
已完成
NCT06041438
| 适应症 | Healthy |
|---|
| 分期 | 1期 |
|---|
| 申办方 | Boehringer Ingelheim |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 14 人 |
|---|
| 干预（药物） | BI 1584862, Itraconazole |
|---|
| 开始日期 | 2023年9月29日 |
|---|
| 完成日期 | 2023年11月10日 |
|---|
| 结果公布日 | 2026年6月3日 |
|---|
摘要
The main objective of this trial is to investigate the effect on the exposure of BI 1584862 in plasma when given as single dose together with multiple doses of itraconazole (Test, T) as compared to BI 1584862 when given alone as oral single dose (Reference, R).
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Within 3 to 4 h before and up to 3 days after BI 1584862 administration. · hour*nanomole/Liter
| BI 1584862 (R) | 999.27 ± NA hour*nanomole/Liter |
|---|
| BI 1584862 + Itraconazole (T) | 7981.53 ± NA hour*nanomole/Liter |
|---|
| Ratio of adjusted geometric means [%] | 798.74 (95% CI 688.62–926.46) |
|---|
Maximum Measured Concentration of BI 1584862 in Plasma (Cmax)
Within 3 to 4 h before and up to 3 days after BI 1584862 administration. · nanomole/Liter
| BI 1584862 (R) | 408.11 ± NA nanomole/Liter |
|---|
| BI 1584862 + Itraconazole (T) | 801.07 ± NA nanomole/Liter |
|---|
| Ratio of adjusted geometric means [%] | 196.29 (95% CI 174.54–220.75) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。